Geron Corp. said it has been cleared by regulators to proceed with the first human test of an embryonic stem cell therapy, designed for patients with spinal-cord injuries. The shares rose as much as 16 percent. The Food and Drug Administration lifted a… Food and Drug Administration – Stem cell – Geron Corporation – Spinal cord injury – Spinal cord

Geron says FDA will allow embryonic stem cell study; safety concerns caused 11-month delay Stem cell – Embryonic stem cell – Biotechnology – Spinal cord injury – Geron Corporation

WASHINGTON The FDA’s blessing Friday of the world’s first clinical trial of a human embryonic stem cell (hESC) therapy has not only launched what may be “the dawn of a new era” for medical treatment, but if successful, the therapies could alleviate much of the burdensome costs plaguing the nation’s health care system, insisted Geron Corp. CEO Thomas Okarma.

Geron Corp. said U.S. regulators cleared the company to proceed with the first medical trial of embryonic stem-cell treatment in patients with spinal-cord injuries. The shares rose as much as 16 percent.

Geron Corp. said it was cleared by U.S. regulators to proceed with the first human test of an embryonic stem-cell therapy, aimed at patients with spinal-cord injuries. The shares rose 17 percent.

Geron will begin tests of its therapy for spinal cord injury. Advanced Cell Technology hopes to follow with a stem cell treatment for blindness. The Food and Drug Administration has cleared Geron, a stem cell company based in Menlo Park, CA, to move forward with clinical tests of its experimental cell therapy for spinal cord injury, which is derived from embryonic stem cells. The company, which …

A therapy for acute spinal cord injuries developed by a UC Irvine scientist will become the world’s first clinical trial of a treatment using human embryonic stem cells. Geron Corp. of Menlo Park announced Friday that the U.S. Food and Drug…

A trial could offer the first glimpse of a technology that may hold vast medical promise but also is embroiled in controversy.

WASHINGTON, July 30 (UPI) — The Food and Drug Administration has given approval to proceed with the world’s first human clinical trial of a human embryonic stem cell-based therapy. Food and Drug Administration – Stem cell – Clinical trial – Biotechnology – Biology

OCEANSIDE, Calif. & HYDERABAD, India—-International Stem Cell Corporation , www.internationalstemcell.com, via its wholly-owned subsidiary, Lifeline Cell Technology® www.lifelinecelltech.com, and Sristi Biosciences, www.sristibio.com, have entered into a distribution agreement for the Lifeline® brand of human cell …

Updated 6:31 p.m. While guarding against making too much of a small Phase 1 study, Athersys Inc. (NASDAQ: ATHX) leaders hinted late Wednesday that their adult stem cell therapy MultiStem eventually could change the way people are treated for heart attacks. The Cleveland, Ohio, biopharmaceutical company reported early results from an ongoing Phase 1 trial to determine [...]

Oman- Stem cell bank to open soon

NPR reports on the confusion among consumers about stem cell therapy. It’s easy to find on websites and other advertisements claims of cures for practically every medical condition, but traditional American medical doctors say that so far stem cell therapy has been proven to work in only a few blood disorders. “Consumers have a hard time sorting out all the stem cell claims out there. Websites …

NPR reports on the confusion among consumers about stem cell therapy. It’s easy to find on websites and other advertisements claims of cures for practically every medical condition, but traditional American medical doctors say that so far stem cell therapy has been proven to work in only a few blood disorders.

Oceanside-based biotech firm International Stem Cell Corp., aka ISCO, said July 20 it will set up an affiliate company in India to develop and manufacture pharmaceutical products.

Editors note: Its been a year since Sparta artist Nina Palumbo first traveled south of the border to Mexico for stem cell treatments to battle her advancing multiple sclerosis.

Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at UCLA’s Jonsson Comprehensive Cancer Center has found. Patients who underwent high doses of …

Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study has found.

US patients spend tens of thousands of dollars travelling to foreign stem cell clinics for treatments that aren’t available in the US. But scientists say some of these clinics are scams, selling unproven, worthless treatments to desperate people with incurable diseases. read more

US patients spend tens of thousands of dollars travelling to foreign stem cell clinics for treatments that aren’t available in the US. But scientists say some of these clinics are scams, selling unproven, worthless treatments to desperate people with incurable diseases.